Lilly did not de-emphasize the tirzepatide brands of Mounjaro for type 2 diabetes and Zepbound for obesity as the primary spurs for its sales growth, but the company pointed out during its fourth-quarter and full-year 2024 sales and earnings call on 6 February that non-incretin products yielded 20% year-over-year growth during Q4.
Key Takeaways
Key Takeaways
- Lilly posted another strong quarter with 45% sales growth during Q4, led by Mounjaro and Zepbound but also non-incretin products such as Verzenio and Taltz.
- In addition, the pharma noted that recently launched products such as Kisunla, Omvoh and Ebglyss are showing early momentum
In Q4, Mounjaro revenue grew by 60% to $3.53bn, while the full-year total of $11.54bn represented 124% growth compared to full-year 2023. Zepbound, meanwhile, posted exponential growth of 985% during Q4, with its $1
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
